Herpes vaccine moves to Phase I clinical trial
Professor Ian Frazer is one of the scientists working on the vaccine for HSV-2 genital herpes. The technology in the vaccine uses a patented optimization technology that offers the potential of a preventative and therapeutic vaccine.
"This clinical trial approval represents a further significant milestone in Allied's commercialization of next generation vaccines that are designed to have the power to both prevent and treat infectious diseases and cancers," Lee Rodne, CEO of Allied Healthcare Group, said. "We are delighted to be working with Professor Frazer and his team on taking this vaccine forward. The clinical trial will also prove the value of this technology in humans for use in a wide range of vaccines."
Genital herpes is caused by the HSV-2 virus. There is currently no cure for the virus, and it can be spread from partner to partner during sexual contact. Current therapies involve using antiviral drugs which can reduce outbreaks and shedding but do not stop the spread of the disease.
The Phase I study will give the vaccination to 20 healthy volunteers. The goal is to check the safety of the vaccine, along with checking to see if the antibody and T-cell response is generated in the volunteers.